Urogen Pharma (URGN) Competitors $13.49 +0.53 (+4.09%) Closing price 07/3/2025 03:11 PM EasternExtended Trading$13.39 -0.10 (-0.74%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. IMVT, HCM, OGN, IBRX, MIRM, XENE, AMRX, BHC, GMTX, and APLSShould you be buying Urogen Pharma stock or one of its competitors? The main competitors of Urogen Pharma include Immunovant (IMVT), HUTCHMED (HCM), Organon & Co. (OGN), ImmunityBio (IBRX), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Urogen Pharma vs. Its Competitors Immunovant HUTCHMED Organon & Co. ImmunityBio Mirum Pharmaceuticals Xenon Pharmaceuticals Amneal Pharmaceuticals Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Immunovant (NASDAQ:IMVT) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment. Do insiders and institutionals have more ownership in IMVT or URGN? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 5.9% of Immunovant shares are owned by insiders. Comparatively, 5.1% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to IMVT or URGN? In the previous week, Urogen Pharma had 5 more articles in the media than Immunovant. MarketBeat recorded 5 mentions for Urogen Pharma and 0 mentions for Immunovant. Urogen Pharma's average media sentiment score of 0.18 beat Immunovant's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Overall Sentiment Immunovant Neutral Urogen Pharma Neutral Which has preferable valuation & earnings, IMVT or URGN? Urogen Pharma has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.74-6.13Urogen Pharma$90.40M6.88-$126.87M-$3.18-4.24 Is IMVT or URGN more profitable? Immunovant has a net margin of 0.00% compared to Urogen Pharma's net margin of -150.68%. Immunovant's return on equity of -80.60% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.60% -71.89% Urogen Pharma -150.68%-97,487.15%-49.57% Which has more volatility and risk, IMVT or URGN? Immunovant has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Do analysts recommend IMVT or URGN? Immunovant currently has a consensus price target of $38.33, indicating a potential upside of 128.12%. Urogen Pharma has a consensus price target of $32.86, indicating a potential upside of 143.57%. Given Urogen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Urogen Pharma is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryUrogen Pharma beats Immunovant on 10 of the 15 factors compared between the two stocks. Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUrogen PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$626.14M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-4.2421.4227.5020.21Price / Sales6.88281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book-64.247.518.045.67Net Income-$126.87M-$55.05M$3.18B$249.13M7 Day PerformanceN/A4.61%2.82%3.30%1 Month Performance174.19%4.89%3.70%5.20%1 Year Performance-10.13%5.84%35.41%21.38% Urogen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUrogen Pharma4.4656 of 5 stars$13.49+4.1%$32.86+143.6%-10.1%$626.14M$90.40M-4.24200IMVTImmunovant1.5707 of 5 stars$15.47-2.1%$38.33+147.8%-35.9%$2.70BN/A-5.65120HCMHUTCHMED1.8467 of 5 stars$15.21+2.5%$19.00+24.9%-9.3%$2.59B$630.20M0.001,811OGNOrganon & Co.4.8251 of 5 stars$9.82+0.7%$18.00+83.3%-50.4%$2.53B$6.40B3.414,000Trending NewsIBRXImmunityBio1.8722 of 5 stars$2.76-3.8%$12.25+343.8%-57.0%$2.53B$14.74M-4.76590Negative NewsGap UpMIRMMirum Pharmaceuticals3.7459 of 5 stars$50.28-0.1%$65.50+30.3%+47.4%$2.49B$336.89M-31.23140News CoverageXENEXenon Pharmaceuticals3.0089 of 5 stars$31.49-1.7%$54.82+74.1%-3.9%$2.46B$9.43M-9.75210AMRXAmneal Pharmaceuticals3.7828 of 5 stars$7.91+1.2%$11.60+46.6%+26.8%$2.45B$2.79B-197.708,100BHCBausch Health Cos3.1468 of 5 stars$6.11-1.1%$7.42+21.4%-2.8%$2.29B$9.63B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+27.8%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.436 of 5 stars$17.62-0.4%$40.05+127.3%-49.2%$2.22B$781.37M-9.84770Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Immunovant Competitors HUTCHMED Competitors Organon & Co. Competitors ImmunityBio Competitors Mirum Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Bausch Health Cos Competitors Gemini Therapeutics Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts